Long-Acting Injectable Medications

Why Long-Acting Injectables?

Medication adherenceMedication Adherence

The extent to which a patient takes medications as prescribed — at the correct dose, frequency, and duration. Poor adherence affects approximately 50% of patients with chronic diseases and is a leadin

is one of the biggest challenges in medicine. Studies consistently show that roughly 50% of patients with chronic conditions do not take their medications as prescribed. Missing doses of antipsychotics, HIV antiretrovirals, or hormonal contraceptives can have serious consequences — relapse, viral rebound, or unintended pregnancy.

Long-acting injectable (LAI) formulations reframe the adherence problem: instead of relying on a patient to take a pill every day, a clinician or patient self-administers an injection once a month, every two months, or even twice a year. The drug is released gradually from an injection depot over weeks or months, maintaining therapeutic levels throughout the dosing interval.

How Extended-Release Depot Formulations Work

The key to a long-acting injectable is controlled, sustained drug release from the injection site. Several technologies achieve this:

Microspheres and microparticles: Drug is encapsulated in biodegradable polymer microspheres (usually poly-lactic-co-glycolic acid, PLGA). After injection, the polymer slowly degrades, releasing drug gradually over weeks to months. Risperdal Consta (risperidone) and Abilify Maintena (aripiprazole) use this approach.

ProdrugProdrug

A pharmacologically inactive compound that is converted to an active drug inside the body through metabolic processes. Prodrugs are designed to improve absorption, reduce side effects, or target drug

ester formulations: A poorly water-soluble ester of the active drug is injected into muscle. It dissolves slowly at the injection site and is converted to the active drug as it is absorbed. Paliperidone palmitate (Invega Sustenna/Trinza) and fluphenazine decanoate use this mechanism.

In situ forming depots: A liquid polymer solution is injected subcutaneously; upon contact with body fluids, it solidifies into a gel depot that releases drug over time. Atrigel technology is used in leuprolide acetate (Eligard) for prostate cancer.

Oil-based solutions: Drug is dissolved in vegetable oil, which slows diffusion from the injection site. Some older antipsychotic depots (haloperidol decanoate) use this.

Crystalline suspensions: Drug in crystal form is injected; crystals dissolve slowly, extending absorption. Cabotegravir (injectable HIV antiretroviral) uses a nanoformulated crystalline suspension.

Routes of Administration

Most LAIs use either intramuscularIntramuscular

A route of drug administration where medication is injected into muscle tissue, providing relatively rapid absorption through the muscle's blood supply. IM injections can deliver both immediate-acting

(IM) or subcutaneousSubcutaneous

A route of drug administration where medication is injected into the layer of fat and connective tissue just beneath the skin. Absorption is slower than IV or IM but is suitable for self-administratio

(SC) injection:

• Intramuscular: Injected into muscle tissue (usually the deltoid or gluteal muscle). Muscles have good blood supply, but drug release depends more on depot technology than vascularity. Many antipsychotic and hormonal LAIs use IM injection.
• Subcutaneous: Injected into adipose tissue (usually abdomen or thigh). Slower absorption than IM due to lower vascularity; suitable for some LAIs designed for monthly to biannual dosing. Cabotegravir/rilpivirine SC injections for HIV are an example.

Some patients can self-inject subcutaneous LAIs at home after training (similar to insulin self-injection), which extends the convenience advantage.

half-lifeHalf-Life

The time required for the plasma concentration of a drug to decrease by 50%. Half-life determines how often a medication needs to be dosed — drugs with shorter half-lives require more frequent dosing

-and-steady-state">Half-Life and Steady-State

The pharmacokinetics of LAIs differ fundamentally from oral drugs. After an injection, drug is absorbed slowly from the depot over the dosing interval. This produces a slow rise to peak concentration and a gradual decline — a much flatter concentration-time profile than a daily oral tablet.

Because the absorption phase is rate-limiting, the effective half-life of an LAI reflects the absorption rate, not the inherent elimination half-life of the drug. Reaching a stable steady-state concentration can take several injection cycles; some LAIs require a loading doseLoading Dose

An initial higher dose of medication given to rapidly achieve therapeutic blood levels before transitioning to a lower maintenance dose. Loading doses are used for drugs with long half-lives that woul

strategy (several doses in rapid succession) to reach therapeutic levels faster.

This flat concentration profile is therapeutically advantageous for drugs where peak-to-trough fluctuations cause side effects or where maintaining minimum effective concentrations is critical.

Therapeutic Areas

Psychiatry: The most established use. Long-acting antipsychotics (paliperidone palmitate, aripiprazole lauroxil, olanzapine pamoate, fluphenazine decanoate, haloperidol decanoate) are used for schizophrenia to reduce relapse rates compared to oral antipsychotics.

HIV: Cabotegravir + rilpivirine (Cabenuva) — monthly or every-two-month injections replacing daily oral regimens for virologically suppressed patients. Lenacapavir (Sunlenca) — twice-yearly SC injection for treatment-experienced patients with drug resistance.

Oncology/Endocrinology: Leuprolide, goserelin, and degarelix (GnRH agonists/antagonists) are given monthly or quarterly for prostate cancer or endometriosis. Octreotide LAR for acromegaly.

Contraception: Medroxyprogesterone acetate (Depo-Provera) — quarterly intramuscular injection for contraception. Subcutaneous formulation allows self-injection.

Addiction: Extended-release naltrexone (Vivitrol) — monthly IM injection for opioid use disorder and alcohol use disorder.

Patient Benefits and Limitations

Benefits: - Dramatically simplifies adherence for chronic conditions - Removes the daily reminder of illness (important for stigmatized conditions like schizophrenia or HIV) - Clinician administration ensures doses are not missed - Flatter drug exposure reduces concentration-related side effects

Limitations: - Injection site reactions (pain, redness, induration) are common - Once administered, the dose cannot be rapidly adjusted or withdrawn if side effects occur — patients must wait for the depot to deplete - Requires clinic visits (though self-injection models are expanding) - Some LAIs require refrigeration (cold chain logistics) - Loading dose strategies add early complexity

Examples of Approved Long-Acting Injectables

• Invega Trinza (paliperidone palmitate 3-month): Once-per-quarter injection for schizophrenia
• Invega Hafyera (paliperidone palmitate 6-month): Twice-yearly injection — the longest-acting antipsychotic available
• Cabenuva (cabotegravir/rilpivirine): Monthly or bimonthly HIV treatment injection
• Sunlenca (lenacapavir): Twice-yearly SC injection for highly treatment-resistant HIV
• Vivitrol (naltrexone ER): Monthly injection for opioid and alcohol use disorders
• Eligard (leuprolide acetate): Monthly to every-6-month injection for prostate cancer

Key Takeaways

• Long-acting injectables solve the adherence challenge by replacing daily pills with monthly or less frequent doses.
• Drug is released from an injection depot via microspheres, prodrug esters, oil suspension, or in situ forming gels.
• IM and SC injection routes are both used; formulation choice determines which is appropriate.
• The effective half-life of an LAI reflects absorption rate, not drug elimination; loading strategies may be needed.
• Key therapeutic areas include schizophrenia, HIV, addiction, prostate cancer, and contraception.
• The inability to rapidly reverse a dose is a meaningful limitation when adverse effects occur.